190 related articles for article (PubMed ID: 22398597)
41. Update in Cystic Fibrosis 2014.
Ong T; Ramsey BW
Am J Respir Crit Care Med; 2015 Sep; 192(6):669-75. PubMed ID: 26371812
[No Abstract] [Full Text] [Related]
42. Cystic fibrosis transmembrane conductance regulator dysfunction and its treatment.
Hull J
J R Soc Med; 2012 Jun; 105 Suppl 2(Suppl 2):S2-8. PubMed ID: 22688363
[No Abstract] [Full Text] [Related]
43. Promising new era dawns for cystic fibrosis treatment.
Corbyn Z
Lancet; 2012 Apr; 379(9825):1475-6. PubMed ID: 22530244
[No Abstract] [Full Text] [Related]
44. CFTR potentiators: not an open and shut case.
Clancy JP
Sci Transl Med; 2014 Jul; 6(246):246fs27. PubMed ID: 25101884
[TBL] [Abstract][Full Text] [Related]
45. [Cystic Fibrosis: toward a genetic treatment; Clostridium difficile versus Clostridium difficile].
Nau JY
Rev Med Suisse; 2015 May; 11(476):1210-1. PubMed ID: 26182641
[No Abstract] [Full Text] [Related]
46. Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor.
Chassagnon G; Hubert D; Fajac I; Burgel PR; Revel MP;
Eur Respir J; 2016 Jul; 48(1):249-52. PubMed ID: 27230445
[No Abstract] [Full Text] [Related]
47. The evidence for long-term benefits of restoration of CFTR function continues to grow.
Boyle MP
Am J Respir Crit Care Med; 2015 Oct; 192(7):774-6. PubMed ID: 26426780
[No Abstract] [Full Text] [Related]
48. Carrier screening for cystic fibrosis in the new era of medications that restore CFTR function.
Massie J; Castellani C; Grody WW
Lancet; 2014 Mar; 383(9920):923-5. PubMed ID: 23992917
[No Abstract] [Full Text] [Related]
49. [FUTURE THERAPIES FOR CYSTIC FIBROSIS].
Fajac I
Rev Prat; 2015 Oct; 65(8):1106-8. PubMed ID: 26749719
[TBL] [Abstract][Full Text] [Related]
50. Appearance of Pancreatic Sufficiency and Discontinuation of Pancreatic Enzyme Replacement Therapy in Children with Cystic Fibrosis on Ivacaftor.
Hutchinson I; McNally P
Ann Am Thorac Soc; 2021 Jan; 18(1):182-183. PubMed ID: 32931706
[No Abstract] [Full Text] [Related]
51. FDA OKs first in vitro route to expanded approval.
Kingwell K
Nat Rev Drug Discov; 2017 Sep; 16(9):591-592. PubMed ID: 28860581
[No Abstract] [Full Text] [Related]
52. Hot off the breath: 'I've a cost for'--the 64 million dollar question.
Bush A; Simmonds NJ
Thorax; 2012 May; 67(5):382-4. PubMed ID: 22407889
[No Abstract] [Full Text] [Related]
53. Combination CFTR modulator therapy in children and adults with cystic fibrosis.
Guimbellot JS; Taylor-Cousar JL
Lancet Respir Med; 2021 Jul; 9(7):677-679. PubMed ID: 33965001
[No Abstract] [Full Text] [Related]
54. FDA deems in vitro data on mutations sufficient to expand cystic fibrosis drug label.
Ratner M
Nat Biotechnol; 2017 Jul; 35(7):606. PubMed ID: 28700545
[No Abstract] [Full Text] [Related]
55. Discovery heralds new approach to the treatment of cystic fibrosis.
Lowe JA
J Med Chem; 2014 Dec; 57(23):9774-5. PubMed ID: 25384240
[No Abstract] [Full Text] [Related]
56. CFTR mutations and cystic fibrosis.
Prescrire Int; 2013 Oct; 22(142):232. PubMed ID: 24298580
[No Abstract] [Full Text] [Related]
57. False dawn for cystic fibrosis disease modifiers?
Holmes D
Nat Rev Drug Discov; 2014 Oct; 13(10):713-4. PubMed ID: 25270946
[No Abstract] [Full Text] [Related]
58. Foundation receives $3.3-billion windfall for Kalydeco.
Senior M
Nat Biotechnol; 2015 Jan; 33(1):8-9. PubMed ID: 25574617
[No Abstract] [Full Text] [Related]
59. Recent advances in cystic fibrosis.
Milla CE; Moss RB
Curr Opin Pediatr; 2015 Jun; 27(3):317-24. PubMed ID: 25888148
[TBL] [Abstract][Full Text] [Related]
60. Remarkable progress toward new treatments for cystic fibrosis.
Eldredge LC; Ramsey BW
Lancet Respir Med; 2014 Dec; 2(12):962-4. PubMed ID: 25466347
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
